Amgen (AMGN) Cuts 42 Jobs in Zug, Switzerland
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
RBC Thinks Amgen's (AMGN) AMG145 Has 'Compelling' Safety Profile Profile; Sees $10B Market Opportunity
November 7, 2012 10:09 AM ESTAmgen (Nasdaq: AMGN) is lower on the session Wednesday amid positive comments out of RBC for its AMG145 drug.
RBC analyst Michael Yee said that AMG145 -- Amgen's late-stage cardio drug -- will grab investor interest over the next year and out-year consensus... More
